In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Neogenomics Inc (NASDAQ: NEO) was $5.67 for the day, up 9.88% from the previous closing price of $5.16. In other words, the price has increased by $9.88 from its previous closing price. On the day, 3.7 million shares were traded. NEO stock price reached its highest trading level at $5.695 during the session, while it also had its lowest trading level at $5.0901.
Ratios:
Our analysis of NEO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 27 ’25 when Kelly Michael Aaron bought 5,000 shares for $7.60 per share. The transaction valued at 38,000 led to the insider holds 5,000 shares of the business.
Stone Warren bought 5,700 shares of NEO for $48,895 on May 12 ’25. The Pres & Chief Operating Officer now owns 108,280 shares after completing the transaction at $8.58 per share. On May 09 ’25, another insider, TETRAULT LYNN A., who serves as the Director of the company, bought 7,000 shares for $8.14 each. As a result, the insider paid 56,974 and bolstered with 7,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 732444928 and an Enterprise Value of 980520768. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06 while its Price-to-Book (P/B) ratio in mrq is 0.85. Its current Enterprise Value per Revenue stands at 1.423 whereas that against EBITDA is -126.096.
Stock Price History:
The Beta on a monthly basis for NEO is 1.54, which has changed by -0.6491337 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $4.72. The 50-Day Moving Average of the stock is -18.47%, while the 200-Day Moving Average is calculated to be -49.91%.
Shares Statistics:
NEO traded an average of 2.21M shares per day over the past three months and 4267290 shares per day over the past ten days. A total of 128.68M shares are outstanding, with a floating share count of 127.39M. Insiders hold about 1.38% of the company’s shares, while institutions hold 96.10% stake in the company. Shares short for NEO as of 1752537600 were 4271941 with a Short Ratio of 1.93, compared to 1749772800 on 4309770. Therefore, it implies a Short% of Shares Outstanding of 4271941 and a Short% of Float of 4.58.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Neogenomics Inc (NEO) reflects the combined expertise of 13.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.05, with high estimates of $0.09 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.18 and $0.07 for the fiscal current year, implying an average EPS of $0.11. EPS for the following year is $0.21, with 13.0 analysts recommending between $0.35 and $0.08.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 13 analysts. It ranges from a high estimate of $192.6M to a low estimate of $181.4M. As of the current estimate, Neogenomics Inc’s year-ago sales were $167.82MFor the next quarter, 13 analysts are estimating revenue of $190.31M. There is a high estimate of $203.3M for the next quarter, whereas the lowest estimate is $186.4M.
A total of 14 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $747M, while the lowest revenue estimate was $717.2M, resulting in an average revenue estimate of $724.35M. In the same quarter a year ago, actual revenue was $660.57MBased on 14 analysts’ estimates, the company’s revenue will be $799.03M in the next fiscal year. The high estimate is $833.9M and the low estimate is $775.8M.
